Aviance Capital Partners’s Novo Nordisk NVO Stock Holding History

Aviance Capital Partners’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.4M	Buy	49,981 +39,895	+396%	+$1.71M	0.25%	86
2026 Q1	$371K	Sell	10,086 -102	-1%	-$4.83K	0.04%	278
2025 Q4	$518K	Sell	10,188 -500	-5%	-$25.6K	0.06%	228
2025 Q3	$593K	Sell	10,688 -34,681	-76%	-$2.03M	0.07%	217
2025 Q2	$3.13M	Buy	45,369 +33,798	+292%	+$2.3M	0.41%	55
2025 Q1	$803K	Hold	11,571	–	–	0.11%	167
2024 Q4	$995K	Sell	11,571 -5,520	-32%	-$597K	0.14%	146
2024 Q3	$2.04M	Buy	17,091 +770	+5%	+$103K	0.27%	93
2024 Q2	$2.33M	Buy	16,321 +98	+0.6%	+$13K	0.33%	75
2024 Q1	$2.08M	Buy	16,223 +1,017	+7%	+$121K	0.31%	80
2023 Q4	$1.57M	Buy	15,206 +5,000	+49%	+$494K	0.34%	69
2023 Q3	$928K	Sell	10,206 -4,000	-28%	-$352K	0.21%	125
2023 Q2	$1.15M	Hold	14,206	–	–	0.24%	119
2023 Q1	$1.13M	Sell	14,206 -2,000	-12%	-$142K	0.25%	111
2022 Q4	$1.1M	Buy	16,206 +8,000	+97%	+$469K	0.26%	111
2022 Q3	$409K	Hold	8,206	–	–	0.1%	183
2022 Q2	$457K	Hold	8,206	–	–	0.1%	185
2022 Q1	$456K	Hold	8,206	–	–	0.08%	190
2021 Q4	$460K	Hold	8,206	–	–	0.08%	196
2021 Q3	$394K	Hold	8,206	–	–	0.07%	207
2021 Q2	$344K	Buy	8,206 +1,124	+16%	+$43.6K	0.06%	211
2021 Q1	$239K	Hold	7,082	–	–	0.05%	246
2020 Q4	$247K	Hold	7,082	–	–	0.05%	236
2020 Q3	$246K	Hold	7,082	–	–	0.06%	225
2020 Q2	$232K	Hold	7,082	–	–	0.06%	219
2020 Q1	$213K	Hold	7,082	–	–	0.07%	198
2019 Q4	$205K	Buy	+7,082	New	+$196K	0.05%	217
2016 Q1	–	Sell	-7,000	Closed	-$203K	–	210
2015 Q4	$203K	Buy	+7,000	New	+$194K	0.07%	180

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Aviance Capital Partners's NVO Position: Q2 2026 in Review

Aviance Capital Partners increased its Novo Nordisk (NVO) stake by 396% in Q2 2026, buying an estimated $1.71M and bringing the position to 49,981 shares worth $2.4M. The position accounts for 0.25% of the portfolio, ranked #86.

Aviance Capital Partners first reported a position in NVO in Q4 2015 and has held it in 28 quarters since. The position peaked at $3.13M in Q2 2025. 1,354 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Aviance Capital Partners held 49,981 shares of Novo Nordisk worth $2.4M as of Q2 2026.
Aviance Capital Partners bought 39,895 Novo Nordisk shares in Q2 2026, an estimated $1.71M.
Novo Nordisk made up 0.25% of Aviance Capital Partners's portfolio in Q2 2026, its #86 holding.
Aviance Capital Partners first reported a position in Novo Nordisk in Q4 2015 and has held it in 28 quarters since.
Aviance Capital Partners's Novo Nordisk position peaked at $3.13M in Q2 2025.
1,354 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Aviance Capital Partners's 13F filing for Q2 2026, filed 31 Jul 2026.